Subjects were randomly segregated into three groups receiving rabeprazole 10 mg once daily ( standard dose in Japan ) , rabeprazole 5 mg once daily , or teprenone ( geranylgeranylacetone ; mucosal protective agent commercially available in Japan ) 50 mg three times per day as an active control .